High B7-H3 expression has been associated with worse clinical outcomes for some cancers, including non–small cell lung cancer, breast cancer, colorectal cancer, prostate cancer, and osteosarcoma (8, 9, 12, 13). This evidence concerns the gene CD276 and Familial prostate cancer.